TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

By

TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

By

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

By

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

By

TScan Therapeutics Announces Exercise of Underwriters’ Option to Purchase Additional Shares

By

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

By

TScan Therapeutics Announces Closing of Upsized Public Offering

By

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

By

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

By